# Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

> **NCT00821080** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 33 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT00821080
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2015-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821080, "Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00821080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*